Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.
Lilly and AstraZeneca both disclosed the subpoenas on Friday, in their first quarter financial reports for 2021. Novartis made a similar disclosure earlier last week in its Q1 financial summary. Sanofi disclosed in March, in its 2020 annual financial report, that it got a subpoena from Vermont Attorney General T.J. Donovan (D) about its participation in the 340B program.
Eli Lilly and AstraZeneca are the latest drug makers to disclose they have received a subpoena from the Vermont attorney general’s office related to their denials of 340B ceiling prices on drugs shipped to contract pharmacies.
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.